THE Australian Competition and Consumer Commission has released its annual report revealing several interventions that affected pharmacy during 2016-17.
Proceedings were begun in 2014 against Pfizer in relation to its "alleged misuse of market power and exclusive dealing in relation to its supply of atorvastatin to pharmacies".
Although the Federal Court dismissed the case, the ACCC has appealed and the case is ongoing.
EBOS' Chemmart Pharmacy franchise came under scrutiny around its promotion of myDNA genetic testing with concerns that the public could have been misled.
Chemmart subsequently withdrew all promotional materials.
In all there were 332 complaints or enquiries relating to pharmaceutical, cosmetic and toiletry goods retailing, the report revealed - see accc.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Oct 17
